Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Paratek Pharma Inc (PRTK)

Paratek Pharma Inc (PRTK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 126,235
  • Shares Outstanding, K 42,219
  • Annual Sales, $ 16,540 K
  • Annual Income, $ -128,790 K
  • 60-Month Beta 1.35
  • Price/Sales 7.58
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.84
  • Number of Estimates 3
  • High Estimate -0.74
  • Low Estimate -0.92
  • Prior Year -1.10
  • Growth Rate Est. (year over year) +23.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.50 +19.60%
on 03/16/20
5.05 -40.79%
on 03/03/20
-1.98 (-39.84%)
since 03/02/20
3-Month
2.50 +19.60%
on 03/16/20
5.28 -43.37%
on 03/02/20
-1.00 (-25.06%)
since 01/02/20
52-Week
2.50 +19.60%
on 03/16/20
6.39 -53.21%
on 04/12/19
-2.73 (-47.73%)
since 04/02/19

Most Recent Stories

More News
Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for All FDA Required Post-marketing Studies for NUZYRA? (omadacycline)

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases...

PRTK : 2.99 (+0.67%)
Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for Security Requirements and U.S. Onshoring of the Manufacturing Supply Chain for NUZYRA? (omadacycline)

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases...

PRTK : 2.99 (+0.67%)
Paratek Pharmaceuticals Announces the Submission of the pre-Emergency Use Authorization Application to the FDA for NUZYRA? (omadacycline)

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases...

PRTK : 2.99 (+0.67%)
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases...

PRTK : 2.99 (+0.67%)
Paratek Pharmaceuticals to Present at the SVB Leerink 9th Annual Global Healthcare Conference

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases...

PRTK : 2.99 (+0.67%)
Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of 21.36% and 87.59%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

PRTK : 2.99 (+0.67%)
Paratek: 4Q Earnings Snapshot

BOSTON (AP) _ Paratek Pharmaceuticals Inc. (PRTK) on Tuesday reported a loss of $27.4 million in its fourth quarter.

PRTK : 2.99 (+0.67%)
Paratek Pharmaceuticals Announces Full Year 2019 Total Revenues of $16.5 Million including NUZYRA(R) (omadacycline) Net Sales of $11.5 Million

-- Paratek Expects Full Year 2020 Total Revenues to be Between $75 and $80 Million including NUZYRA Net Sales of Approximately $66 Million

PRTK : 2.99 (+0.67%)
Paratek Announces License Grant to Almirall for SEYSARA(R) (sarecycline) for Greater China Region

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases...

PRTK : 2.99 (+0.67%)
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020

Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will...

PRTK : 2.99 (+0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade PRTK with:

Business Summary

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use...

See More

Key Turning Points

2nd Resistance Point 3.14
1st Resistance Point 3.06
Last Price 2.99
1st Support Level 2.88
2nd Support Level 2.78

See More

52-Week High 6.39
Fibonacci 61.8% 4.90
Fibonacci 50% 4.44
Fibonacci 38.2% 3.99
Last Price 2.99
52-Week Low 2.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar